Opinion
Video
Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.
Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study
Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL